DBV Technologies H1 net loss widens to $98 million

• DBV Technologies posted a net loss of USD 98 million for the six months ended June 30, 2026, widening from USD 69 million a year earlier.
• Operating income slipped to USD 1.6 million from USD 2.2 million, on lower French research tax credit income as the focus shifts to commercial readiness.
• R&D expense rose to USD 64.6 million from USD 55.2 million, while operating expenses climbed to USD 100.1 million from USD 69.9 million.
• Cash and cash equivalents totaled USD 174.9 million at June 30, 2026, with funding expected into the third quarter of 2027.
• FDA talks continued for the VIASKIN Peanut Patch BLA in children 4-7, with submission now expected in the third quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DBV Technologies SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607161601PRIMZONEFULLFEED1001213127) on July 16, 2026, and is solely responsible for the information contained therein.